


ABSTRACT OF THE DISCLOSURE

This invention provides compounds defined by Formula I



or a pharmaceutically acceptable salt thereof,
wherein R^1 , Q, D, V^1 , m, and R^2 are as defined in the specification. The invention
also provides pharmaceutical compositions comprising a compound of Formula I,
or a pharmaceutically acceptable salt thereof, as defined in the specification,
10 together with a pharmaceutically acceptable carrier, diluent, or excipient. The
invention also provides methods of inhibiting an MMP-13 enzyme in an animal,
comprising administering to the animal a compound of Formula I, or a
pharmaceutically acceptable salt thereof. The invention also provides methods of
treating a disease mediated by an MMP-13 enzyme in a patient, comprising
15 administering to the patient a compound of Formula I, or a pharmaceutically
acceptable salt thereof, either alone or in a pharmaceutical composition. The
invention also provides methods of treating diseases such as heart disease,
multiple sclerosis, osteo- and rheumatoid arthritis, arthritis other than osteo- or
rheumatoid arthritis, cardiac insufficiency, inflammatory bowel disease, heart
20 failure, age-related macular degeneration, chronic obstructive pulmonary disease,
asthma, periodontal diseases, psoriasis, atherosclerosis, and osteoporosis in a
patient, comprising administering to the patient a compound of Formula I, or a
pharmaceutically acceptable salt thereof, either alone or in a pharmaceutical
composition. The invention also provides combinations, comprising a compound
25 of Formula I, or a pharmaceutically acceptable salt thereof, together with another
pharmaceutically active component as described in the specification.